Atossa Therapeutics, Inc. (NASDAQ:ATOS) Short Interest Update

Atossa Therapeutics, Inc. (NASDAQ:ATOS - Get Free Report) was the target of a large decrease in short interest in the month of November. As of November 30th, there was short interest totalling 11,600,000 shares, a decrease of 6.8% from the November 15th total of 12,450,000 shares. Based on an average daily volume of 628,500 shares, the days-to-cover ratio is presently 18.5 days.

Atossa Therapeutics Trading Down 4.5 %

NASDAQ ATOS traded down $0.05 on Monday, reaching $1.07. The stock had a trading volume of 1,196,618 shares, compared to its average volume of 1,061,297. The company has a market capitalization of $134.61 million, a price-to-earnings ratio of -5.20 and a beta of 1.21. The business has a 50 day moving average price of $1.35 and a 200 day moving average price of $1.33. Atossa Therapeutics has a 1 year low of $0.70 and a 1 year high of $2.31.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. StockNews.com cut shares of Atossa Therapeutics from a "hold" rating to a "sell" rating in a research note on Monday, November 18th. HC Wainwright reiterated a "buy" rating and set a $7.00 price target on shares of Atossa Therapeutics in a report on Thursday. Finally, Ascendiant Capital Markets upped their price target on shares of Atossa Therapeutics from $6.50 to $7.00 and gave the stock a "buy" rating in a research report on Monday, December 9th.

Institutional Investors Weigh In On Atossa Therapeutics

Several hedge funds have recently modified their holdings of the business. Geode Capital Management LLC grew its holdings in Atossa Therapeutics by 1.6% during the 3rd quarter. Geode Capital Management LLC now owns 2,814,446 shares of the company's stock worth $4,278,000 after acquiring an additional 44,762 shares during the last quarter. State Street Corp grew its holdings in shares of Atossa Therapeutics by 4.2% in the 3rd quarter. State Street Corp now owns 1,732,221 shares of the company's stock valued at $2,633,000 after buying an additional 69,180 shares during the period. Renaissance Technologies LLC raised its stake in Atossa Therapeutics by 11.9% during the 2nd quarter. Renaissance Technologies LLC now owns 1,550,910 shares of the company's stock worth $1,846,000 after buying an additional 164,540 shares during the period. Bank of New York Mellon Corp grew its stake in Atossa Therapeutics by 3,160.5% in the second quarter. Bank of New York Mellon Corp now owns 411,667 shares of the company's stock valued at $490,000 after acquiring an additional 399,041 shares during the period. Finally, Barclays PLC increased its stake in Atossa Therapeutics by 280.9% during the 3rd quarter. Barclays PLC now owns 167,718 shares of the company's stock worth $255,000 after purchasing an additional 123,683 shares in the last quarter. 12.74% of the stock is owned by institutional investors.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.